GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease

Yazhou Li, Kara B. Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A. Bailey, Harold W. Holloway, David Tweedie, Tracyann Perry, Mark P. Mattson, Dimitrios Kapogiannis, Kumar Sambamurti, Debomoy K. Lahiri, Nigel H. Greig

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Type 2 (T2) diabetes mellitus (DM) has been associated with an increased incidence of neurodegenerative disorders, including Alzheimer's disease (AD). Several pathological features are shared between diabetes and AD, including dysfunctional insulin signaling and a dysregulation of glucose metabolism. It has therefore been suggested that not only may the two conditions share specific molecular mechanisms but also that agents with proven efficacy in one may be useful against the other. Hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (Ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (GLP-1), on stress-induced toxicity in neuronal cultures and on amyloid-β protein (Aβ) and tau levels in triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced diabetes. Ex-4 ameliorated the toxicity of Aβ and oxidative challenge in primary neuronal cultures and human SH-SY5Y cells in a concentration-dependent manner. When 11 to 12.5 month old female 3xTg AD mice were challenged with STZ or saline, and thereafter treated with a continuous subcutaneous infusion of Ex-4 or vehicle, Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels. Furthermore, brain levels of Aβ protein precursor and Aβ, which were elevated in STZ 3xTg-AD mice, were significantly reduced in Ex-4 treated mice. Brain tau levels were unaffected following STZ challenge, but showed a trend toward elevation that was absent following Ex-4 treatment. Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance.

Original languageEnglish (US)
Pages (from-to)1205-1219
Number of pages15
JournalJournal of Alzheimer's Disease
Volume19
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Amyloid
Alzheimer Disease
Animal Models
Peptides
Streptozocin
Insulin
Incretins
Serum Amyloid A Protein
Subcutaneous Infusions
Glucose
Glucagon-Like Peptide 1
Protein Precursors
Glucose Intolerance
Experimental Diabetes Mellitus
Glucagon-Like Peptide-1 Receptor
Staphylococcal Protein A
Brain
exenatide
Neurodegenerative Diseases
Type 2 Diabetes Mellitus

Keywords

  • 3xTg-AD mice
  • Alzheimer's disease
  • Amyloid-β peptide
  • Amyloid-β protein precursor
  • Dementia
  • Diabetes
  • Extendin-4
  • Glucagon-like peptide-1
  • Neuroprotection
  • Streptozocin
  • Tau

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. / Li, Yazhou; Duffy, Kara B.; Ottinger, Mary Ann; Ray, Balmiki; Bailey, Jason A.; Holloway, Harold W.; Tweedie, David; Perry, Tracyann; Mattson, Mark P.; Kapogiannis, Dimitrios; Sambamurti, Kumar; Lahiri, Debomoy K.; Greig, Nigel H.

In: Journal of Alzheimer's Disease, Vol. 19, No. 4, 2010, p. 1205-1219.

Research output: Contribution to journalArticle

Li, Y, Duffy, KB, Ottinger, MA, Ray, B, Bailey, JA, Holloway, HW, Tweedie, D, Perry, T, Mattson, MP, Kapogiannis, D, Sambamurti, K, Lahiri, DK & Greig, NH 2010, 'GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease', Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1205-1219. https://doi.org/10.3233/JAD-2010-1314
Li, Yazhou ; Duffy, Kara B. ; Ottinger, Mary Ann ; Ray, Balmiki ; Bailey, Jason A. ; Holloway, Harold W. ; Tweedie, David ; Perry, Tracyann ; Mattson, Mark P. ; Kapogiannis, Dimitrios ; Sambamurti, Kumar ; Lahiri, Debomoy K. ; Greig, Nigel H. / GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. In: Journal of Alzheimer's Disease. 2010 ; Vol. 19, No. 4. pp. 1205-1219.
@article{6e0d5c5993aa4ad3beb6528aed5d73ef,
title = "GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease",
abstract = "Type 2 (T2) diabetes mellitus (DM) has been associated with an increased incidence of neurodegenerative disorders, including Alzheimer's disease (AD). Several pathological features are shared between diabetes and AD, including dysfunctional insulin signaling and a dysregulation of glucose metabolism. It has therefore been suggested that not only may the two conditions share specific molecular mechanisms but also that agents with proven efficacy in one may be useful against the other. Hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (Ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (GLP-1), on stress-induced toxicity in neuronal cultures and on amyloid-β protein (Aβ) and tau levels in triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced diabetes. Ex-4 ameliorated the toxicity of Aβ and oxidative challenge in primary neuronal cultures and human SH-SY5Y cells in a concentration-dependent manner. When 11 to 12.5 month old female 3xTg AD mice were challenged with STZ or saline, and thereafter treated with a continuous subcutaneous infusion of Ex-4 or vehicle, Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels. Furthermore, brain levels of Aβ protein precursor and Aβ, which were elevated in STZ 3xTg-AD mice, were significantly reduced in Ex-4 treated mice. Brain tau levels were unaffected following STZ challenge, but showed a trend toward elevation that was absent following Ex-4 treatment. Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance.",
keywords = "3xTg-AD mice, Alzheimer's disease, Amyloid-β peptide, Amyloid-β protein precursor, Dementia, Diabetes, Extendin-4, Glucagon-like peptide-1, Neuroprotection, Streptozocin, Tau",
author = "Yazhou Li and Duffy, {Kara B.} and Ottinger, {Mary Ann} and Balmiki Ray and Bailey, {Jason A.} and Holloway, {Harold W.} and David Tweedie and Tracyann Perry and Mattson, {Mark P.} and Dimitrios Kapogiannis and Kumar Sambamurti and Lahiri, {Debomoy K.} and Greig, {Nigel H.}",
year = "2010",
doi = "10.3233/JAD-2010-1314",
language = "English (US)",
volume = "19",
pages = "1205--1219",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease

AU - Li, Yazhou

AU - Duffy, Kara B.

AU - Ottinger, Mary Ann

AU - Ray, Balmiki

AU - Bailey, Jason A.

AU - Holloway, Harold W.

AU - Tweedie, David

AU - Perry, Tracyann

AU - Mattson, Mark P.

AU - Kapogiannis, Dimitrios

AU - Sambamurti, Kumar

AU - Lahiri, Debomoy K.

AU - Greig, Nigel H.

PY - 2010

Y1 - 2010

N2 - Type 2 (T2) diabetes mellitus (DM) has been associated with an increased incidence of neurodegenerative disorders, including Alzheimer's disease (AD). Several pathological features are shared between diabetes and AD, including dysfunctional insulin signaling and a dysregulation of glucose metabolism. It has therefore been suggested that not only may the two conditions share specific molecular mechanisms but also that agents with proven efficacy in one may be useful against the other. Hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (Ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (GLP-1), on stress-induced toxicity in neuronal cultures and on amyloid-β protein (Aβ) and tau levels in triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced diabetes. Ex-4 ameliorated the toxicity of Aβ and oxidative challenge in primary neuronal cultures and human SH-SY5Y cells in a concentration-dependent manner. When 11 to 12.5 month old female 3xTg AD mice were challenged with STZ or saline, and thereafter treated with a continuous subcutaneous infusion of Ex-4 or vehicle, Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels. Furthermore, brain levels of Aβ protein precursor and Aβ, which were elevated in STZ 3xTg-AD mice, were significantly reduced in Ex-4 treated mice. Brain tau levels were unaffected following STZ challenge, but showed a trend toward elevation that was absent following Ex-4 treatment. Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance.

AB - Type 2 (T2) diabetes mellitus (DM) has been associated with an increased incidence of neurodegenerative disorders, including Alzheimer's disease (AD). Several pathological features are shared between diabetes and AD, including dysfunctional insulin signaling and a dysregulation of glucose metabolism. It has therefore been suggested that not only may the two conditions share specific molecular mechanisms but also that agents with proven efficacy in one may be useful against the other. Hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (Ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (GLP-1), on stress-induced toxicity in neuronal cultures and on amyloid-β protein (Aβ) and tau levels in triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced diabetes. Ex-4 ameliorated the toxicity of Aβ and oxidative challenge in primary neuronal cultures and human SH-SY5Y cells in a concentration-dependent manner. When 11 to 12.5 month old female 3xTg AD mice were challenged with STZ or saline, and thereafter treated with a continuous subcutaneous infusion of Ex-4 or vehicle, Ex-4 ameliorated the diabetic effects of STZ in 3xTg-AD mice, elevating plasma insulin and lowering both plasma glucose and hemoglobin A1c (HbA1c) levels. Furthermore, brain levels of Aβ protein precursor and Aβ, which were elevated in STZ 3xTg-AD mice, were significantly reduced in Ex-4 treated mice. Brain tau levels were unaffected following STZ challenge, but showed a trend toward elevation that was absent following Ex-4 treatment. Together, these results suggest a potential value of Ex-4 in AD, particularly when associated with T2DM or glucose intolerance.

KW - 3xTg-AD mice

KW - Alzheimer's disease

KW - Amyloid-β peptide

KW - Amyloid-β protein precursor

KW - Dementia

KW - Diabetes

KW - Extendin-4

KW - Glucagon-like peptide-1

KW - Neuroprotection

KW - Streptozocin

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=77950352189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950352189&partnerID=8YFLogxK

U2 - 10.3233/JAD-2010-1314

DO - 10.3233/JAD-2010-1314

M3 - Article

C2 - 20308787

AN - SCOPUS:77950352189

VL - 19

SP - 1205

EP - 1219

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -